Should measures be taken to reduce the risk of human parvovirus (B19) infection by transfusion of blood components and clotting factor concentrates?
- 1 September 1994
- journal article
- Published by Wiley in Transfusion
- Vol. 34 (9) , 744-746
- https://doi.org/10.1046/j.1537-2995.1994.34994378271.x
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Human parvoviruses: implications for transfusion medicineTransfusion, 1994
- B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentratesThe Lancet, 1994
- Human parvovirus B19 infection in bone marrow transplantation patientsAmerican Journal of Hematology, 1993
- Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studiesBritish Journal of Haematology, 1993
- Management of Sickle Cell Disease; Lessons from the Jamaican Cohort StudyBlood Reviews, 1993
- Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates1Vox Sanguinis, 1990
- Detection by PCR of hepatitis C virus in factor VIII concentratesThe Lancet, 1990
- Transmission of Human Parvovirus B19 by Coagulation Factor ConcentratesVox Sanguinis, 1990
- Pure Red-Cell Aplasia of 10 Years' Duration Due to Persistent Parvovirus B19 Infection and Its Cure with Immunoglobulin TherapyNew England Journal of Medicine, 1989
- TRANSMISSION OF SERUM PARVOVIRUS-LIKE VIRUS BY CLOTTING-FACTOR CONCENTRATESThe Lancet, 1983